Search

Displaying results 2121 - 2130 of 10000 in total
  1. Drug

    Flutemetamol (18F)

    go.drugbank.com/drugs/DB09151
    ApprovedInvestigational

    It is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  3. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. … It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side.

    Mixtures: TRIAMETERENO E HIDROCLOROTIAZIDA CAPSULAS, PROPRA COMP RATIOPHARM
  4. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis. … in MS therapy.

  5. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … ] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared

    Categories: Retinoids for Topical Use in Acne
  6. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    as compared to "classical" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors. … [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations

  7. Target

    ATPase GET3

    go.drugbank.com/bio_entities/BE0000750
    TargetHumans

    This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion.

    Synonyms: Transmembrane domain recognition complex 40 kDa ATPase subunit
  8. Drug

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10788
    ApprovedInvestigational

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
  9. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    In a prospective clinical study of patients with an open tibial fracture, administration of dibotermin alfa resulted in faster fracture- or wound-healing, significantly fewer secondary invasive interventions … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

  10. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of bone by osteoclasts.